Update shared on04 Sep 2025
As key metrics including the discount rate (7.16%) and net profit margin (16.85%) remained stable, the consensus analyst price target for Medpace Holdings was unchanged at $422.27.
What's in the News
- Medpace completed a repurchase of 1,754,264 shares (5.89% of shares outstanding) for $518.54 million in Q2 2025, bringing the total buyback under its current program to 14.76% of shares outstanding and $1.27 billion since October 2022 (Key Developments).
- Updated 2025 full-year guidance expects revenue of $2.42 billion to $2.52 billion (14.7% to 19.5% growth YoY), GAAP net income of $405 million to $428 million, and diluted EPS between $13.76 and $14.53 (Key Developments).
- The National Institutes of Health (NIH) has told staff not to cancel additional research projects for now, following previous funding cuts under the Trump administration (Periodicals).
- The NIH's temporary pause on grant cancellations led shares of companies like Illumina and Thermo Fisher to rebound, while Medpace shares reduced earlier losses but remained in the red (Periodicals).
- Medpace's updated guidance demonstrates resilience despite recent sector volatility connected to shifting federal research funding policies (Combined).
Valuation Changes
Summary of Valuation Changes for Medpace Holdings
- The Consensus Analyst Price Target remained effectively unchanged, at $422.27.
- The Discount Rate for Medpace Holdings remained effectively unchanged, at 7.16%.
- The Net Profit Margin for Medpace Holdings remained effectively unchanged, at 16.85%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.